Clinical trial
MInimal Residual Disease Adapted Strategy
NCT04934475 · Intergroupe Francophone du Myelome, Other · Active, not recruiting
Key facts
| NCT number | NCT04934475 |
|---|---|
| Title | MInimal Residual Disease Adapted Strategy |
| Official title | MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study |
| Acronym | MIDAS |
| Lead sponsor | Intergroupe Francophone du Myelome, Other |
| Collaborators | Amgen Industry Sanofi Bristol-Myers Squibb |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug, Procedure |
| Interventions | Isatuximab, ASCT |
| Enrollment | 791 |
| Start date | Dec 8, 2021 |
| Primary completion | Sep 30, 2024 |
| Completion | Sep 30, 2028 |
| First posted | Jun 22, 2021 |
| Last update posted | Nov 7, 2024 |
| Countries | Belgium, France, Reunion |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: